Chronic disease in the elderly: back to the future of internal medicine. by Fabbri, Leonardo & R., Ferrari
Key points 
k The ageing of the population has increased
the prevalence of chronic diseases, which
represent a huge proportion of human illness.
k The two most important risk factors
underlying the most frequent chronic diseases
of the elderly are tobacco use and obesity.   
k The most important comorbidities are cardio-
vascular diseases and chronic respiratory
diseases, particularly COPD.
k Comorbidities may not only contribute to the
severity of a patient's clinical manifestations,
but they may also complicate its treatment,
and they are therefore important to recognise
and treat effectively.
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The most important and preventable
chronic diseases (cardiovascular diseases,
cancer, chronic respiratory diseases and dia-
betes) increase in frequency and severity with
age [1–3]. Chronic diseases share largely pre-
ventable risk factors, the most important and
preventable being smoking and obesity [4, 5].
Individual chronic diseases, e.g. chronic heart
failure (CHF) and chronic obstructive pul-
monary disease (COPD), almost never develop
alone but invariably develop together with
one or more chronic comorbidities [6, 7]. More
than half of elderly people (≥65 years) have at
least three chronic medical conditions, and a
significant proportion have five or more [8]. 
Obviously, such co-existing illnesses can
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Educational aims
k To increase the interest of chest physicians in multiple chronic comorbidities in the elderly.
k To define the most important and frequent comorbidities in elderly patients, particularly 
those with COPD.
k To provide updated information on the most common chronic diseases present in the elderly. 
k To emphasise the limitations of single disease-oriented clinical practice guidelines, and the 
need for a more comprehensive "internistic" approach to patients with multiple chronic 
comorbidities.
k To suggest that chronic inflammation might represent the common pathogenetic link 
between the different chronic diseases present in the elderly.
Summary
Elderly people are often affected by two or more chronic diseases, more frequently cardio-
vascular diseases, chronic respiratory diseases, metabolic syndrome and cancer. These
most frequent chronic diseases share largely preventable risk factors, the most important
being smoking and obesity, and may be linked to chronic systemic inflammation. Co-
existing chronic diseases affect the course of the primary disease and alter the efficacy
and safety of its management. Current clinical practice is dominated by the "single-
disease" approach, which has major limitations, and there is increasing evidence that a
patient-oriented approach that takes into account the several co-existing components of
chronic disease is required. This "change of concept" implies the need for medical spe-
cialists to extend their expertise to broader diagnostic and treatment approaches that
are traditionally the purview of internal medicine. This new approach also requires a dif-
ferent approach to clinical research and teaching, followed by extensive rewriting of
medical textbooks and remodelling of teaching curricula to reflect the complexity of the
patient affected by chronic diseases.
j
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affect the course of the primary disease, and alter
the efficacy and safety of its management. Thus,
while we continue to diagnose and assess the
severity of single chronic diseases, we urgently
need to re-assess the terminology and devise new
criteria for the diagnosis and management of pat-
ients affected by more than one chronic disease.   
Each component of a chronic disease, i.e.
each comorbidity, can be classified into one of
four categories: 1) causal (diseases with a com-
mon pathophysiology, such as coronary artery
disease and myocardial infarction, emphysema
and COPD); 2) complicating (disease-specific
complicating morbidity, such as pneumonia in
COPD or thromboembolism in CHF); 3) concur-
rent co-existing chronic morbidity without any
known causal relationship with the index dis-
ease (such as gastritis and CHF or COPD); and 4)
intercurrent (interacting acute illness, usually lim-
ited in time, such as colds or influenza in CHF or
COPD) [9]. 
Chronic diseases make up a huge proportion
of human illness [10]. Up to 35 million people
were projected to die in 2005 from heart dis-
ease, stroke, cancer and other chronic diseases
(figure 1). Excluding cancer, cardiovascular dis-
ease (30% of projected total worldwide deaths
in 2005), chronic respiratory diseases (7%) and
diabetes (2%) are the most frequent chronic
degenerative disorders [1–3]. An unprecedented
increase in chronic degenerative disorders is
expected in the next 10 years, and this is of great
concern to the health authorities [1, 3]; thus,
chronic disease is a particularly important area
in which to implement prevention strategies and
to ensure high-quality care. The two most import-
ant risk factors underlying chronic diseases,
which are key to any population-wide strategy of
control, are tobacco use and obesity. Both can be
prevented and controlled. If these risk factors
were eliminated, at least 80% of premature
heart disease and strokes would be prevented,
80% of type 2 diabetes would be prevented,
and more than 40% of cancers would be pre-
vented. Comprehensive and integrated strate-
gies to reduce these risks would have a major
effect on this range of diseases [1–3, 11].
Patients with chronic diseases are usually
>50 years and have multiple comorbidities [2, 3,
12, 13]. Because of exclusion criteria, clinical tri-
als on chronic disease select younger people with
milder disease and underestimate the frequency
of comorbidities, which may affect 80–90% of
the elderly population [8]. For example, clinical
trials show that COPD occurs in 20% of patients
with CHF, whereas population studies show a
higher prevalence [14, 15]. Likewise, clinical trials
show that CHF may occur in >20% of patients
with COPD, whereas population studies show a
higher prevalence [15]. Thus, comorbidities are
quite frequent and important: not only may they
contribute to the severity of the patient's clinical
manifestations, but they may also complicate its
treatment, and they are, therefore, important to
recognise and treat effectively [8, 15, 16]. 
Both CHF and COPD may also be associated
with metabolic disorders, e.g. diabetes [17] and
osteoporosis [18], and with other chronic condi-
tions, e.g. anaemia [19, 20], renal failure [21],
rheumatoid arthritis [22, 23], Helicobacter pylori
infection [24] and erectile dysfunction [25].
Patients presenting with chronic inflammatory
disease show a higher prevalence of various
types of cancer [26], possibly linked to systemic
inflammation [27]. 
COPD
COPD is a nonspecific term referring to a set of
conditions that develop progressively as a result
of various disease processes, namely emphysema
and bronchiolitis, in response to inhalation of irri-
tants, primarily cigarette smoke [28, 29].
Considering the systemic nature of the inflam-
matory response to irritants, particularly cigarette
smoke [30], there is increasing evidence that lung
abnormalities are not the only conditions respon-
sible for respiratory symptoms such as dyspnoea.
Other factors which play a role include the chron-
ic comorbidities that develop along with COPD,
particularly CHF, coronary and peripheral vascular
diseases, and metabolic syndrome [7, 31].
Comorbidities are highly likely to affect health
outcomes in COPD, and COPD patients are more
likely to die from cardiovascular complications or
cancer than from respiratory failure [7].
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Figure 1
Projected global distribution of
total deaths by major causes for
2005. Thirty-five million people
were projected to die in 2005,
mainly from chronic diseases.
Figure reprinted with permission
[2].
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Progressive respiratory failure accounts for
approximately one-third of COPD-related deaths;
therefore, factors other than progression of lung
disease must play a substantial role in COPD
mortality. The most common comorbidities that
have been described in association with COPD
are hypertension, diabetes, coronary artery dis-
ease [32, 33], heart failure [15], pulmonary infec-
tions, cancer [26] and pulmonary vascular dis-
ease [7] (figure 2). The number of pre-existing
comorbidities in patients with COPD is associat-
ed with increased in-hospital mortality [33].
Comorbid conditions that have been associated
with an increased mortality risk in COPD patients
include chronic renal failure, pulmonary hyper-
tension, right heart failure [34] and pulmonary
vascular disease [35]. Underlying heart diseases
have not been consistently associated with a
higher mortality risk. However, since COPD is fre-
quently under-reported, it is difficult to accurately
estimate how comorbid conditions influence
COPD mortality or, conversely, how COPD affects
the outcome of other diagnoses [7]. 
There is a growing body of evidence that
indicates that persistent low-grade systemic
inflammation is present in stable COPD. Low-
grade systemic inflammation has been implicat-
ed in the pathogenesis of cardiovascular events
and chronic myopathy of skeletal muscle. Since
COPD patients suffer from excess morbidity and
mortality related to cardiovascular events, it has
been suggested that systemic inflammation may
be the common link [36].
In conclusion, COPD is one of the leading
causes of mortality and morbidity in the world,
yet little is known about the prevalence and
importance of comorbid conditions and specific
causes of death in patients with COPD.
Considering that patients with COPD die not of
COPD but primarily of comorbid conditions, par-
ticularly cardiovascular diseases and lung cancer,
and that the pharmacological treatment of
COPD is only symptomatic, a more comprehen-
sive approach to comorbidities and particularly
to those that are preventable and treatable, such
as cardiovascular and metabolic, may represent
the only opportunity for the next several years to
modify the natural history of COPD.  
CHF
CHF is the leading cause of hospitalisation in
older adults, and it is also an important cause of
death and chronic disability [37]. Heart failure in
the elderly differs in many respects from heart
failure occurring during middle age. In particular,
the diagnosis and treatment of heart failure in
the elderly are often complicated by the pre-
sence of multiple cardiac and noncardiac comor-
bid conditions, many of which have important
implications for the care of the older heart-failure
patient [38].
CHF is the only common cardiovascular con-
dition whose prevalence is increasing, especially
in the elderly [6, 37]. It is often the expression of
end-stage cardiac disease, when half of the
patients diagnosed with CHF will be dead
within 5 years. Increasing prevalence, hospitali-
sations and deaths have made CHF a major
chronic condition in Western countries and a
major cause of death worldwide.
Comorbidities are common in CHF, particu-
larly in the elderly [38]. The most common ones
are chronic coronary and peripheral artery dis-
eases (>50%), arterial hypertension (~50%),
diabetes (20–30%), COPD (20–30%) and
anaemia (20–30%), all of which affect severity,
morbidity, hospitalisation and mortality [12, 39]
(table 1).
Systemic arterial
hypertension 
The diagnosis of arterial hypertension depends
on repeated occurrences of higher-than-normal
systolic and/or diastolic blood pressure [40]. An
untreated hypertensive patient is at great risk of
experiencing disabling or fatal left ventricular fail-
ure, myocardial infarction, cerebral haemorrhage
or infarction, or renal failure at an early age [40].
Arterial hypertension is the most important risk
factor predisposing to stroke [40]. It is one of
three risk factors (along with cigarette smoking
and hypercholesterolaemia) predisposing to
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Figure 2
Relationship between rate per
10,000 of selected medical events
and their relative risk (RR) in COPD
versus non-COPD patients >65
years old. Figure reprinted with
permission from [32].
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coronary atherosclerosis. The higher the blood
pressure and the more severe the changes in the
retina, the worse the prognosis. Fewer than 5%
of patients with group 4 or malignant hyperten-
sion characterised by papilloedema and <10% of
patients with group 3 changes in the fundus sur-
vive 1 year without treatment. Effective medical
control of hypertension will prevent or forestall
most complications and will prolong life in pat-
ients with isolated systolic or diastolic hyperten-
sion [40]. 
Coronary artery disease is the most common
cause of death among treated hypertensive
patients. Systolic blood pressure is a more import-
ant predictor of fatal and nonfatal cardiovascu-
lar events than diastolic blood pressure. In a
follow-up of males screened for the Multiple Risk
Factor Intervention Trial, overall mortality was
related to systolic blood pressure, regardless of
diastolic blood pressure. Arterial hypertension is
a frequent comorbidity of most chronic diseases
[41], e.g. up to 40% in COPD [25, 42], CHF [12,
39, 43] and in renal failure [44], and it is an
important component of the cardiometabolic
syndrome [4, 45].
Atherosclerosis,
coronary and peripheral
vascular diseases
Vascular diseases include coronary artery disease
and peripheral arterial disease, a term that
encompasses a range of non-coronary arterial
syndromes that are caused by the altered struc-
ture and function of the arteries that supply the
brain, the visceral organs and the limbs. Vascular
diseases are caused primarily by atherosclerosis
and thromboembolic pathophysiological pro-
cesses that alter the normal structure and func-
tion of the aorta, its visceral arterial branches
and the arteries of the lower extremities [46, 47]. 
As atherosclerosis is the most common cause
of coronary and peripheral artery disease world-
wide, the epidemiology and clinical conse-
quences of peripheral arterial disease are closely
associated with classic atherosclerosis risk fac-
tors (smoking, diabetes, hypertension, hyperlipid-
aemia, family history and post-menopausal
state) and more recently defined risk factors (e.g.
hyperhomocysteinaemia) [46, 47]. 
Coronary vascular diseases and peripheral
arterial disease are often associated, and the
prognosis of patients with peripheral arterial dis-
ease is characterised by an increased risk for
cardiovascular ischaemic events due to concomi-
tant coronary artery disease and cerebrovascular
disease. The relative prevalence of coronary and
cerebral atherosclerosis depends on the criteria
used to establish the diagnosis. In approximately
one-third to one-half of patients presenting with
peripheral arterial disease, evidence of coronary
artery disease is based on clinical history and
electrocardiogram; in two-thirds of patients, it is
based on an abnormal stress test.
The majority of individuals with lower-extrem-
ity peripheral artery disease do not experience
recognisable limb ischaemic symptoms; by this
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Study Results
Hypertension
BRAUNSTEIN et al. [6] 55% had HT and 11% severe HT in the Medicare study 
(n=122,630 patients)
HO et al. [7] 39% of males and 59% of females had HT in the 
LEVY et al. [8] Framingham study
GUSTAFSSON et al. [9] 27% of the males and 22% of the females had HT in the
Danish Diamond study (n=5,491 patients)
HIMMELMAN [10] At least 50% of patients with HT developed HF
Diabetes
KANNEL et al. [24] Risk for developing HF in young males and females with 
DM (2.20 and 5.37, respectively)
SHINDLER et al. [25] In the SOLVD study 15% in the prevention trial and 26%
in the treatment trial had DM
COHN et al. [26] Similar results in the V-HeFT II trial (26%) had DM
Consensus trial [27] 23% developed DM in the CONSENSUS trial
RYDEN et al. [28] 19% developed DM in the ATLAS study
SHINDLER et al. [25] In the SOLVD registry (n=6,076 patients) 23% had DM
ZANNAD et al. [29] In the French registry study EPICAL 26% had DM
BRAUNSTEIN et al. [6] In the Medicare study (n=122,630 patients) 31% had DM
STRATTION et al. [30] Interrelationship between HbA1c levels and incidence of
HF
IRIBARREN et al. [31] Each 1% increase in HbA1c was associated with 8% 
increased risk of developing HF
PAOLISSO et al. [32] Whole body insulin resistance is prevalent in HF patients
with either ischaemic or idiopathic dilated cardiomyopathy
SWAM et al. [33] Similar results as in PAOLISSO et al. [32]
COPD
BRAUNSTEIN et al. [6] In the Medicare study 26% of patients had COPD
GUSTAFSSON et al. [9] In the Danish Diamond study 22% had COPD 
NI et al. [53] In this study only 10% had COPD
MCCULLOUGH et al. [54] In this emergency department study 21% of the 
patients had COPD
Anaemia
TANNER et al. [59] The prevalence of anaemia was 15%
EZEKOWITZ et al. [60] The prevalence of anaemia was 17%
SILVERBERG et al. [61] The prevalence of anaemia was 50% and in patients 
with severe HF 80%
KOMAJDA [62] In this review the prevalence of anaemia and its clinical 
characteristics are discussed
Table reprinted with permission from [39]; the numbers between brackets refer to references in [39].
Table 1 Epidemiological data on the prevalence of 
hypertension (HT), diabetes (DM), COPD and anaemia 
in patients with heart failure (HF)
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definition they are "asymptomatic", which
implies the absence of classic intermittent clau-
dication. Individuals with asymptomatic lower-
extremity peripheral artery disease do not enjoy
a benign prognosis, because most have systemic
atherosclerotic disease. These individuals are
characterised by a risk factor profile comparable
to that of individuals with symptomatic lower-
extremity peripheral artery disease [47]. Patients
with vascular disorders can usually be assured
that an accurate anatomical diagnosis will be
made with modern non-invasive vascular diag-
nostic techniques (e.g. ankle- and toe-brachial
indices, segmental pressure measurements,
pulse volume recordings, duplex ultrasound
imaging, Doppler waveform analysis and exer-
cise testing). These tests will usually provide ade-
quate information for creation of a therapeutic
plan [47]. 
As a consequence of co-existing coronary
and cerebrovascular disease, there is an
increased risk of myocardial infarction, stroke
and cardiovascular death in patients with lower-
extremity peripheral arterial disease [47].
Systemic complications and comorbidities of
atherosclerosis, and chronic coronary and peri-
pheral vascular diseases include myocardial
infarction [47, 48], stroke [49], renal failure [48,
50], erectile dysfunction [51], rheumatoid arthri-
tis [22], diabetes and dementia [52].
Metabolic syndrome
Metabolic syndrome is a complex disorder and
an emerging clinical challenge, recognised by
the findings of abdominal obesity, elevated
triglycerides, atherogenic dyslipidaemia, elevat-
ed blood pressure, high blood glucose and/or
insulin resistance [53]. Metabolic syndrome is
also characterised by a prothrombotic state and
a proinflammatory state. Central pathophysio-
logical features of metabolic syndrome include:
1) insulin resistance; 2) atherogenic dysli-
pidaemia; 3) arterial hypertension, which occurs
frequently in persons with insulin resistance; 4) a
proinflammatory state, with increases in acute-
phase reactants (e.g. C-reactive protein); and 5)
a prothrombotic state, with increases in plas-
minogen activator inhibitor-1 and fibrinogen
[53]. The risk of mortality and of major cardio-
vascular events increases two- to four-fold in indi-
viduals affected by metabolic syndrome or type
2 diabetes, relative to those without metabolic
disease [54], and metabolic modulation is
altered in COPD [55]. 
Inflammation is an important risk factor in
cardiovascular disease and diabetes mellitus,
and adding inflammatory markers to the defini-
tion of metabolic syndrome improves the predic-
tion of cardiovascular diseases and diabetes.
Elevated hs-C-reactive protein levels may also be
predictive of development of metabolic syn-
drome, suggesting that systemic inflammation
plays the key pathogenetic role in metabolic syn-
drome and its comorbidities [56]. Diabetes has
been estimated to account for 1.1 million deaths
in 2005, but it is related to many more fatalities,
because, although people might live for years
with diabetes, their deaths are usually recorded
as being caused by heart disease, kidney failure
or chronic respiratory diseases [11].
Osteoporosis
Osteoporosis is a common and preventable
disorder of the older adult skeleton that pre-
disposes an individual to an increased risk of
fracture, a major cause of disability in older
adults [57]. Most patients with osteoporosis
have an identifiable cause of bone loss. Osteo-
porosis is often associated with chronic cardio-
vascular and respiratory diseases [58] and COPD
[18], and, like most chronic conditions, benefits
from physical activity [59], particularly in the
elderly.  
Muscle wasting
Cachexia (derived from the Greek kakos (bad)
and hexis (condition)) is characterised by accel-
erated loss of skeletal muscle and poor respon-
siveness to nutritional interventions [60, 61].
Cachectic patients exhibit changes in the
metabolism of proteins, lipids and carbohydrates
that are thought to be related to systemic inflam-
mation; although systemic inflammation is
considered an effect of individual chronic condi-
tions, e.g. COPD, CHF, renal failure and cancer, it
is, in fact, very similar in both pathogenetic
mechanisms and clinical manifestations in the
various chronic diseases [60]. 
Anaemia
Anaemia is frequently associated with chronic ill-
nesses such as CHF, with inflammatory diseases
such as rheumatoid arthritis, with chronic infec-
tious disorders, and with cancer [20]. Anaemia
in chronic illness is characterised by weakness,
fatigue, cachexia and poor nutritional state, and
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by impaired mood, cognitive functions and qual-
ity of life [62]. It has been suggested that
anaemia to some extent contributes to exercise
limitation and dyspnoea in chronic illness [63]. 
Anaemia also frequently occurs in patients
with COPD [20]. Inadequate haemoglobin levels
could aggravate tissue hypoxia and carry a nega-
tive prognostic impact. Blood cell transfusion in
anaemic COPD patients reduces minute ventila-
tion and the work of breathing [64], suggesting
that correcting low haemoglobin levels could
alleviate dyspnoea and improve exercise capacity.
In a small set of anaemic ventilator-dependent
COPD patients, raising haemoglobin levels to
>12 g·dL-1 seemed to improve patients enough
to make ventilator weaning possible. A reduced
haematocrit was found to be an independent
predictor of poor outcomes in COPD patients fol-
lowing elective open abdominal aortic aneurysm
resection [65]. 
CRF
Chronic renal failure (CRF) is a gradual and pro-
gressive loss of the ability of the kidneys to
excrete waste, concentrate urine and conserve
electrolytes. It most often results from any dis-
ease that causes gradual loss of kidney function.
It can range from mild dysfunction to severe kid-
ney failure, and progression may continue to
end-stage renal disease, which is associated with
important comorbidities [66]. CRF and end-
stage renal disease affect more than two out of
1,000 people in the USA. Diabetes and hyper-
tension (high blood pressure) account for
approximately two-thirds of the cases of CRF and
end-stage renal disease. Most body systems are
affected by CRF, and fluid retention and uraemia
can cause many complications. A recent study
showed that both renal failure and ischaemic
heart disease were highly relevant to the prog-
nosis of COPD patients discharged from hospital
after an acute exacerbation. These comorbid dis-
eases probably acted as markers of frailty by
increasing the fatality rate of further COPD exac-
erbations [67].
Single disease versus
patient-oriented
guidelines
Clinical practice guidelines are increasingly being
used as performance indicators, and have been
shown to substantially improve the quality of
clinical care. However, most clinical practice
guidelines ignore the fact that the majority of
individuals with a chronic disease have one or
more chronic comorbidities, e.g. COPD, CHF,
peripheral artery disease, diabetes or non-life-
threatening cancer, that may have a major im-
pact, particularly in the elderly [68]. Thus,
although comorbidities are quite frequent in
clinical practice, most evidence-based, disease-ori-
ented diagnostic and treatment strategies over-
look them [8, 9]. It is, therefore, evident that
clinical practice guidelines, designed largely by
specialty-dominated committees for managing
single diseases, provide clinicians with little guid-
ance in caring for older patients with multiple
chronic diseases. 
Treatment or even diagnosis of a disease
might interact negatively or positively with the
treatment or natural course of a co-existing dis-
ease [8, 69]. For example, treatment of exacer-
bations of COPD includes oral corticosteroids,
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which may not be recommended if the patient
also has diabetes mellitus; β-blockers are recom-
mended for CHF but might have adverse effects
in patients who also have asthma or COPD.
Conversely, statins, which are used primarily as
lipid-lowering agents in the treatment of
metabolic syndrome, have potent anti-inflamma-
tory properties that might positively affect
comorbidities of metabolic syndrome, e.g. COPD,
CHF and vascular diseases [70–73]. However,
the most recent guidelines for COPD and CHF
refer only marginally to comorbidities and do
not include them in the assessment of severity
and do not refer one to the other [28, 37].
Chronic inflammation
as the common link 
The systemic effects of exposure to cigarette
smoke and atmospheric particles were recently
nicely reviewed [5, 7]. Cigarette smoke and
atmospheric particles stimulate the bone marrow
to release leukocytes, such as neutrophils and
monocytes, as well as platelets. The bone mar-
row's response is related to the intensity of expo-
sure of alveolar macrophages to particles and to
their release of mediators as a response to these
particles [74–77]. Circulating cytokines and
chemokines (e.g. interleukin (IL)-6 and IL-1) and
granulocyte-macrophage colony-stimulating fac-
tor increase after exposure to ambient particles,
and they stimulate the bone marrow [74].
Tumour necrosis factor-α and IL-1 are "acute
response" cytokines that, together with IL-6, are
responsible for initiation of the acute-phase
response [78]. Together, these cytokines have the
ability to elicit a systemic inflammatory response
characterised by an increase in circulating leuko-
cytes, platelets, and proinflammatory and pro-
thrombotic proteins [78]. This response generates
C-reactive protein, fibrinogen and other coagula-
tion factors, all of which have been associated
with thromboembolic cardiovascular events. This
response also has the ability to activate circulat-
ing leukocytes and the endothelium of the
vascular bed to promote leukocyte-endothelial
adhesion and migration [78]. Cigarette smoke
and pollutants, like infectious organisms, activate
alveolar macrophages, bronchial epithelial cells
and other cellular elements in the airways, par-
ticularly in genetically susceptible individuals
[79]. Once activated, these cells produce a variety
of signalling molecules, chemokines and
cytokines, e.g. IL-8, which recruits neutrophils;
macrophage chemotactic protein-1, which recruits
monocytes; and interferon-γ-inducible protein-10,
which recruits lymphocytes [78]. Additionally,
these cells stimulate the synthesis and release of
growth factors, elastolytic enzymes and metallo-
proteinases, which, by themselves, may promote
emphysematous changes in lung parenchyma
and airway remodelling [80, 81]. Systemic
inflammation is also present in COPD and, on a
cross-sectional basis, has been linked with cardiac
ischaemic events, suggesting that systemic
inflammation may contribute to the causal path-
way, linking COPD, in particular, with cardiovas-
cular complications [7]. 
Thus, there is a growing body of evidence to
indicate that persistent low-grade systemic
inflammation is present in all components of the
chronic diseases, and that chronic systemic
inflammation may be the link between them
(figure 3) (reviewed in references  [7] and  [36]).
For example, if systemic inflammation is a key
mechanism for atherosclerosis, patients suffering
from conditions associated with systemic inflam-
mation should have an excess risk of cardiovas-
cular morbidity and mortality. Atherosclerosis is a
progressive disease characterised by accumula-
tion of lipids, fibrous tissue and inflammatory
cells in arteries. Although the pathogenesis of
atherosclerosis is complex and multifactorial, per-
sistent, low-grade systemic inflammation is
believed to be one of the central events leading
to plaque formation. There are strong epidemio-
logical data linking systemic inflammation to
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Figure 3
The central role of inflammation,
particularly reactive oxygen
species (ROS), C-reactive protein
(CRP) and tumour necrosis factor
(TNF)-α, in comorbidities associ-
ated with COPD. Figure reprinted
with permission from [36].
Educational questions
1. What are the main causes
of death in patients with 
COPD?
a) Cardiovascular diseases.
b) Lung cancer.
c) Respiratory failure.
d) Renal failure.
2. The prevalence of COPD in
patients with chronic heart
failure is close to:
a) 70%
b) 50%
c) 20%
d) 10%
3. The relative risk of diabetes
in subjects with COPD is 
close to:
a) 1
b) 4
c) 2
d) 3
4. The deaths attributable to
smoking are mainly:
a) COPD.
b) Diabetes.
c) Cancer.
d) Cardiovascular diseases.
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atherosclerosis, ischaemic heart disease, strokes
and coronary deaths [82]. Under normal physio-
logical conditions (and without external insults),
the human endothelium does not support leuko-
cyte adhesion, which is the building block of
plaque genesis. However, in an inflammatory
state (such as diabetes, COPD or obesity), the
endothelium begins to overexpress surface adhe-
sion molecules, such as vascular cell adhesion
molecule-1, that allow circulating white blood
cells to adhere to damaged endothelial surfaces.
Once the white cells adhere to the endothelium,
they trigger a whole series of inflammatory reac-
tions.
Conclusion
In conclusion, two or more chronic diseases
almost invariably develop together in the same
patient, particularly in the elderly, often making
it difficult to establish a proper diagnosis and
assessment of severity. The current clinical prac-
tice is dominated by the "single-disease"
approach, which has major limitations, whereas
there is increasing evidence that a patient-
oriented approach that takes into account the
several co-existing components of chronic dis-
ease is required. This "change of concept"
implies the need for medical specialists to
extend their expertise to broader diagnostic and
treatment approaches that are traditionally the
purview of internal medicine. This new approach
also requires a different approach to clinical
research and teaching, followed by extensive
rewriting of medical textbooks and remodelling
of teaching curricula to reflect the complexity of
the patient affected by chronic disease.
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